What does a basic metabolic panel with elevated blood urea nitrogen (BUN) of 32 mg/dL, elevated serum creatinine of 1.52 mg/dL, and reduced estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73 m² indicate?

Stage 3b Chronic Kidney Disease with Moderate Renal Impairment

These laboratory values indicate Stage 3b chronic kidney disease (CKD) with moderate renal impairment, requiring nephrology referral and comprehensive evaluation for underlying causes and cardiovascular risk management. 1, 2

Laboratory Interpretation

Your metabolic panel reveals three interconnected abnormalities:

• eGFR of 38 mL/min/1.73 m²: This definitively places you in CKD Stage 3b (eGFR 30-44 mL/min/1.73 m²), indicating moderately to severely decreased kidney function 1, 2, 3

• Creatinine 1.52 mg/dL: Elevated above normal range, reflecting reduced glomerular filtration 4

• BUN 32 mg/dL: Elevated, indicating accumulation of nitrogenous waste products 5

The combination of elevated BUN and creatinine with reduced eGFR confirms impaired kidney function rather than isolated laboratory abnormalities.

Clinical Significance and Risk Stratification

Stage 3b CKD carries substantial implications for morbidity and mortality:

• Cardiovascular risk is markedly elevated - CKD at this stage significantly increases your risk of cardiovascular disease and death 1, 2

• Progressive kidney disease risk - Without intervention, there is risk of progression to Stage 4-5 CKD and eventual end-stage renal disease requiring dialysis 1

• Metabolic complications - At eGFR <45 mL/min/1.73 m², complications including anemia, bone disease, and electrolyte abnormalities become increasingly common 6

According to the risk stratification grid, Stage 3b CKD falls in the orange to red zone, requiring monitoring 2-3 times per year and consideration for nephrology referral 2

Immediate Actions Required

Nephrology referral is strongly recommended for patients with eGFR <45 mL/min/1.73 m² 1, 2. The 2022 Diabetes Care guidelines specifically state referral should occur when eGFR falls below 30 mL/min/1.73 m², but the 2022 Mayo Clinic field guide recommends earlier referral for Stage 3b disease 1, 2.

Essential Diagnostic Workup

1. Assess for albuminuria/proteinuria: Obtain urine albumin-to-creatinine ratio (UACR) to complete CKD staging and assess cardiovascular risk 1, 6, 2

2. Identify underlying cause:

   • Screen for diabetes (HbA1c, fasting glucose)
   • Assess blood pressure control
   • Review medication list for nephrotoxic agents
   • Consider renal ultrasound to evaluate for structural abnormalities or obstruction 5

3. Evaluate for CKD complications:

   • Complete blood count (assess for anemia)
   • Comprehensive metabolic panel including calcium, phosphorus, bicarbonate
   • Parathyroid hormone level
   • Vitamin D level 6

4. Cardiovascular risk assessment: Given the markedly elevated CV risk with Stage 3b CKD 1, 2

Management Priorities

Blood Pressure Control

If hypertensive with any degree of albuminuria, initiate ACE inhibitor or ARB therapy 1. Monitor serum creatinine and potassium within 1-2 weeks of starting therapy - an increase in creatinine up to 20% is acceptable and does not indicate progressive deterioration 3.

Medication Adjustments

Critical: Many medications require dose adjustment at eGFR <45 mL/min/1.73 m². Review all current medications with your physician or pharmacist 7. Avoid nephrotoxic agents including NSAIDs.

Monitoring Frequency

With Stage 3b CKD, kidney function should be monitored 2-3 times per year with serum creatinine, eGFR, and UACR 2. More frequent monitoring is needed if:

• Rapid eGFR decline (>5 mL/min/1.73 m² per year)
• Significant albuminuria develops
• New medications are started

Diabetes Management (if applicable)

If diabetic, consider SGLT2 inhibitors or GLP-1 receptor agonists, which have proven kidney and cardiovascular protective effects in CKD 1, 2.

Important Caveats

The elevated BUN deserves specific attention: While BUN elevation typically reflects reduced GFR, research shows BUN can have independent prognostic significance beyond eGFR alone 8, 9. Factors that can elevate BUN disproportionately include:

• High protein intake relative to kidney function
• Volume depletion/dehydration
• Gastrointestinal bleeding
• Catabolic states
• Heart failure 8, 9, 10

Ensure adequate hydration status is assessed, as prerenal factors could be contributing to the laboratory abnormalities 5.

Do not delay evaluation: Stage 3b CKD represents a critical window for intervention. Early nephrology involvement, identification of reversible causes, and aggressive risk factor management can slow progression and reduce cardiovascular events 1, 2.